Editorial on the relationship between suPAR and CKD, published in NEJM

Wed Oct 21 2020

“A suPAR Biomarker for Chronic Kidney Disease”, published in the New England Journal of Medicine

The worldwide epidemic of Chronic Kidney Disease constitutes a death sentence in regions of the world where renal-replacement therapies are not available. Since decreased renal function is only detected after substantial kidney injury has already occurred, there is an urgent need to identify new biomarkers that accurately determine the risk of impending chronic kidney disease while renal function is still well preserved and there is higher likelihood that medical interventions can slow or prevent progression.

Studies that show that intervention based on suPAR levels is beneficial could cement a relationship between suPAR and chronic kidney disease.

Read the editorial here.

+700

published suPAR studies in leading medical journals

The suPARnostic® brand consists of 3 products:

Photo of The suPARnostic® Quick Triage kit

Quick Triage

A Point of Care Solution

Photo of suPARnostic® TurbiLatex

TurbiLatex

For Automated Systems

Photo of suPARnostic® ELISA

ELISA Assay

Clinical and Research

Would you like to know more?

If you have any questions regarding our products or business, write to us here

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

Sign up for our newsletter

By signing up for our newsletter you will receive the latest news about our products.

Thank you!

You'll hear from us shortly.

An error occured!

Please try again, or contact us by e-mail if the problem persist.

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates